PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative
2002871
Ordering Recommendation
Provides genetic confirmation of APL. Predict relapse risk and monitor for minimal residual disease post-consolidation therapy.
Mnemonic
PML QNT
Methodology
Reverse Transcription Polymerase Chain Reaction
Performed
RNA isolation: Sun-Sat
Assay: Sun, Tue, Thu
Reported
2-7 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Time SensitiveTime Sensitive

Additional Technical InformationAdditional Technical Information
 
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL). OR 3 mL bone marrow (Min: 1 mL). Specimens must be received within 48 hours of collection due to lability of RNA.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Refer to report.

See Compliance Statement D: www.aruplab.com/CS  
Note
This assay qualifies as COG approved for the AAML0631 study.
CPT Code(s)
81315
Components
Component Test Code*Component Chart Name
2002872PML-RARA Translocation, t(15;17)
2002874PML-RARA Translocation, t(15;17) Quant
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • AMPL' APL
  • APL MRD
  • APL Post-consolidation therapy testing
  • PML-RARA fusion types, A, B, B variant
  • PML-RARA long, short, variable types
  • PML-RARA S, L, V forms
  • PML_RARA fusion types
  • Quantitative PML
  • t(15;17)